Catalent Expands Controlled-Release Manufacturing Facility - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Catalent Expands Controlled-Release Manufacturing Facility
Catalent invests $35 million in major expansion of its Winchester facility

Catalent is investing nearly $35 million in a major expansion of its controlled-release drug manufacturing facility in Winchester, Kentucky. Construction started on June 12, 2013, with the expansion expected to be completed by October 2014. The company’s 100,000 square-foot facility will be expanded by almost 80,000 square feet and will add as many as 90 new employees at the expanded site.

“The expanded Winchester facility will provide our customers with enhanced access to custom equipment capabilities and our market-leading controlled release solutions and technologies,” said Steve Havel, General Manager of Catalent’s Winchester facility, in a press statement.

The Winchester facility, opened in 1992, is one of the company’s main sites for advanced oral controlled-release drug formulation and manufacturing and this expansion follows several investments Catalent has made in advanced delivery technologies globally.

“As with Winchester, Catalent continues to invest to meet the most critical needs of the industry, including recently announced inhalation facility expansion in North Carolina, our recently completed biologics expansion in Wisconsin, and our two new ventures in China, which will focus on softgel technologies and clinical trial supplies.”


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here